Background
==========

Parkinson\'s disease (PD) is a neurodegenerative disorder that is characterized by muscle tremors in stationary limbs, bradykinesia (slowed movement) and difficulty initiating and sustaining movements, and affects 1--2% of the population older than sixty years of age \[[@B1]-[@B5]\]. As the disease progresses, both the sense of balance and the memory of the affected individual deteriorate. Post-mortem analysis reveals the selective loss of dopaminergic neurons from the substantia nigra region of the brain. Filamentous protein inclusions, known as Lewy bodies, are found within the neuronal cell bodies of the affected area, in most but not all PD patients \[[@B4]\]. Although the majority of PD cases appear to be sporadic, about 5--15% have been determined to have an inherited basis \[[@B6],[@B7]\]. Recently, mutations in a number of genes have been identified as causes of PD and many of these genes are associated with the ubiquitin/proteasome protein degradation pathway.

Mutations in the gene encoding the α-synuclein protein lead to the development of Autosomal Dominant PD (ADPD) \[[@B8],[@B9]\]. The α-synuclein protein is an abundant 140 amino acid, cytosolic protein found at the pre-synaptic region of neurons \[[@B10],[@B11]\]. α-synuclein appears to be involved in the biosynthesis of dopamine \[[@B12],[@B13]\]. Mutations in the α-*synuclein*gene \[[@B8],[@B9]\] may lead to enhanced oligomerization and fibril formation of the α-synuclein protein \[[@B14]-[@B16]\].

Autosomal Recessive Juvenile Parkinson\'s disease (ARJP), another inherited form of PD, has been attributed to a number of point mutations and deletions of the *parkin*gene \[[@B17]-[@B19]\]. ARJP is specifically characterized by a very early age of onset, mostly before forty years of age, and the absence of Lewy bodies \[[@B20]-[@B22]\]. In humans, the *parkin*gene encodes a 465 amino acid protein \[[@B17]\] that functions as one of a number of E3 ubiquitin protein ligases, components of the ubiquitin/proteasome degradation pathway \[[@B23]\]. Ubiquitin protein ligases act to identify damaged, misfolded, and short-lived proteins to mediate the ubiquitination (the sequential attachment of a number of ubiquitin monomers) of these proteins, which are targeted to the proteasome \[[@B24],[@B25]\]. Experiments in tissue culture have demonstrated that parkin can ubiquitinate a number of substrates including a glycosylated form of α-synuclein \[[@B26]\], the Pael receptor \[[@B27]\], CDCrel-1 \[[@B28]\], the α-synuclein-binding protein synphilin-1 \[[@B29]\], and parkin itself \[[@B28],[@B30]\]. The loss of *parkin*may lead to an accumulation of one or a number of proteins in sufficient quantities to cause neuronal cell death.

The interaction of parkin with α-synuclein suggests a common mechanism underlying inherited forms of PD. Indeed, elevated expression of *parkin*protects neuronal explants from the toxicity associated with expression of α-*synuclein*\[[@B26],[@B31]\]. The disease inducing-forms of α-synuclein may prevent its degradation and result in toxic accumulation. In ARJP, functional parkin protein is lost along with the ability to mediate the ubiquitination of glycosylated α-synuclein and may lead to the accumulation of this protein \[[@B26]\]. Our working hypothesis is that aspects of parkin-mediated protein degradation are compromised in PD.

The first *Drosophila melanogaster*model of PD was generated by the conditional expression of human α-*synuclein* in transgenic *Drosophila*\[[@B32]\]. Flies that express α-*synuclein*, in either a pan-neural or dopaminergic neuron specific manner, show a marked age-dependent loss of dorsal-medial dopaminergic neurons. Cytoplasmic inclusions were observed in α-*synuclein*-expressing flies approximately 20 days after eclosion. While control flies exhibit a strong negative geotaxis, these transgenic flies prematurely lose their climbing ability. In addition, expression of α-*synuclein*in the developing eye results in precocious degeneration of the retina. In this model expression of a number of genes are dysregulated prior to the onset of neurodegeneration \[[@B33]\]. These features recapitulate the main behavioural and pathological phenotypes of PD and provide an excellent model system to study the biological basis of the disease.

The *Drosophila*α-*synuclein*based model has been used to investigate a number of aspects of PD. Pharmacological agents, such as the dopamine precursor levodopa, dopamine receptor agonists (bromocriptine, pergolide and SK&F38393), and the anticholinergic atropine, were demonstrated to modify the age-dependent loss of climbing ability \[[@B34]\]. Co-expression of the molecular chaperone *HSP70*gene with α-*synuclein*prevented dopaminergic neuronal degeneration \[[@B35]\]. Interference with endogenous chaperone activity accelerated the toxicity of α-synuclein demonstrating a role for chaperones in the pathology of the disease. Suppression of HSP90, a negative regulator of the heat shock factor 1, by feeding flies geldanamycin prevents dopaminergic neuronal cell death \[[@B36]\]. Recently, the expression of human *parkin*has been shown to suppress the loss of dopaminergic neurons induced by α-*synuclein*in *Drosophila*\[[@B37]\]. This model has proven to be an effective tool in the investigation of the biological basis of PD.

To investigate the role of *parkin*in the α-*synuclein*-based model of Parkinson\'s disease in *Drosophila*, we have characterized and expressed the *Drosophila*homologue of *parkin*in this model. Our results demonstrate that *parkin*can counteract the effects of α-*synuclein*on climbing activity and retinal degeneration.

Results
=======

Characterization of *Drosophila melanogaster parkin*
----------------------------------------------------

The *Drosophila melanogaster parkin*homologue was identified through a search of the Berkeley Drosophila Genome Project (BDGP) utilizing the tBlastn search algorithm. The *parkin*gene is located on the left arm of the third chromosome, in the polytene chromosome section 78C within the genomic scaffolding region AE003593 (BDGP), and consists of 6 exons over 2.2 kb (Figure [1A](#F1){ref-type="fig"}). A search of the genome for additional *parkin*homologues revealed none. Our analysis confirmed the sequence of *parkin*to be identical to that reported by the BDGP (AY058754.1). Two potential initiation codons for the parkin protein are separated by 42 base pairs at the 5\' region of the transcript. As the second potential start codon is preceded by CAAA, a match to the *Drosophila*Kozak consensus sequence (C/A)AA(A/C)ATG) of translation initiation \[[@B38]\], we have assigned this as the most likely start codon. Furthermore, of the preceding fourteen potential codons only two use preferred codons \[[@B39]\] (data not shown). The *Drosophila parkin*gene was reported by Greene and colleagues \[[@B40]\], while the current experiments were being conducted.

The parkin protein is well conserved
------------------------------------

The *Drosophila melanogaster*parkin protein has been reported to be 42% identical to human parkin \[[@B40]\] (Figure [1B](#F1){ref-type="fig"}). Parkin protein homologues were identified from *Rattus norvegicus*(NM_020093.1) and *Mus musculus*(AB019558.1) via the tblastn algorithm of the National Center for Biotechnology Information (NCBI). Both the *R. norvegicus*and *M. musculus*homologues were found to have 44% identity and 60% similarity to *D. melanogaster*parkin when analysed by the blast2 algorithm (Figure [1B](#F1){ref-type="fig"}). In addition, we have determined that the *Anopheles gambiae*sequence XM316606.1 \[[@B41]\] is a homologue of *parkin*. Like *D. melanogaster*, the *A. gambiae*transcript has two potential in-frame translation start sites. The Kozak sequence prior to the first ATG is very poor, however the second site closely resembles the consensus sequence and therefore it is very likely the start site. We determined that the theoretical *A. gambiae*parkin protein has 65% identity and 79% similarity to *D. melanogaster*parkin (Figure [1B](#F1){ref-type="fig"}). The parkin protein appears to be highly conserved at the amino acid sequence level.

Alignment of *D. melanogaster*parkin protein sequences with the *A. gambiae*, *R. norvegicus*, *M. musculus*and *H. sapiens*homologues reveals conservation of the protein throughout a number of characteristic domains, including the [Ub]{.ul}iquitin- [l]{.ul}ike Domain (UBL), the [U]{.ul}nique [P]{.ul}arkin [D]{.ul}omain (UPD), the [R]{.ul}eally [I]{.ul}nteresting [N]{.ul}ew [G]{.ul}ene finger 1 (RING1) domain, the [I]{.ul}n- [B]{.ul}etween [R]{.ul}ing (IBR) domain, and the RING2 domain (Figure [1B](#F1){ref-type="fig"}). In the amino-terminal region of the proteins, the first 15 amino acids are well conserved between *A. gambiae*and *D. melanogaster*, but absent in the mammalian proteins. The human UBL shows very high similarity (62%) to human ubiquitin \[[@B17]\]. Correspondingly the *Drosophila*UBL (Figure [1B](#F1){ref-type="fig"}, green box) was found to have 43% identity and 67% similarity to *Drosophila*ubiquitin (AAA29007; data not shown). The second highly conserved region is unique to parkin and has been termed the unique parkin domain (UPD) \[[@B42]\] (Figure [1B](#F1){ref-type="fig"}, red box). *D. melanogaster*and *A. gambiae*share a similar eight amino acid insertion in the UPD (Figure [1B](#F1){ref-type="fig"}). There are two RING-finger domains that are defined by the consensus sequence C-X~2~-C-X~9\...39~-C-X~1\...3~-H-X~2\...3~-C/H-X~2~-C-X~4\...48~-C-X~2~-C where X can be any amino acid (Figure [1B](#F1){ref-type="fig"}, blue boxes) \[[@B43]\]. These RING-finger domains flank a cysteine-rich domain designated the In-Between Ring (IBR) domain (Figure [1B](#F1){ref-type="fig"}, black box) \[[@B44]\]. These three domains are responsible for binding to specific E2 ubiquitin conjugating enzymes \[[@B23],[@B28],[@B30]\]. Between the RING1 and the IBR domains there is an eighteen amino acid stretch of high conservation with the sequence (N/H)S(L/F)I(K/E)(E/D)(I/L)HHF(K/R)(L/I)LX(R/E)E(E/Q)Y. A 41 amino acid segment separates the IBR and RING2 domains, and while the first half of this segment is not well conserved the second half is highly conserved with the sequence AX(E/Q)ARW(D/E)XA(S/T)(N/K)X(T/A)IKX(S/T)TKP. The carboxy-terminus is well conserved and has the following sequence M(G/A)XHWF(G/D)(-/V), suggesting a possible conserved function for the tail of the protein. As parkin undergoes self-ubiquitination \[[@B28]\], conserved potential ubiquitination sites (lysine residues) were identified. There is a lysine residue that is completely conserved at K-42 of the dipterans and this corresponding residue is K-27 in mammals (Figure [1B](#F1){ref-type="fig"}, black arrow). The mouse and rat *parkin*homologues have been recently compared to *Drosophila parkin*\[[@B45]\], however a number of the above features were not discussed. Overall parkin appears to be highly conserved between mammalian and dipteran species suggesting conservation of function among these species.

*parkin*suppresses degeneration of the ommaditial array in flies that express α-*synuclein*in the eye
-----------------------------------------------------------------------------------------------------

We generated stable transgenic flies that can conditionally express *parkin*when the UAS/Gal4 expression system is utilized \[[@B46]\]. *In situ*hybridization was used to confirm *parkin*expression in transgenic *Drosophila*(data not shown). Expression of *parkin*was directed to the developing eye using the *GMR-Gal4*transgene resulting in no obvious alteration of the eye (data not shown). *In vitro*and cell culture research suggests that parkin can prevent α-*synuclein*-induced toxicity \[[@B31],[@B47]\]. Expression of human α-*synuclein*in the *Drosophila*eye causes premature deterioration of the retina \[[@B32]\]. To examine if parkin could prevent α-*synuclein*-induced degeneration, we co-expressed *parkin*with human α-*synuclein*in the developing eye. Cross-sections of the retinas of one-day-old flies that express α-*synuclein*appear to be intact, as previously described (Figure [2A](#F2){ref-type="fig"}) \[[@B32]\]. The retinas of one-day-old flies that express both α-*synuclein*and *parkin*also appear normal (Figure [2B,2C](#F2){ref-type="fig"}). As previously described, the retinas of thirty-day-old flies that express α-*synuclein*show signs of premature degeneration \[[@B32]\]. Degeneration of the normal architecture of the eye is apparent (Figure [2D](#F2){ref-type="fig"}, black arrows) and reflects the disruption of the normal placement and alignment of the photoreceptors and supporting cells. In contrast, thirty-day-old flies that express α-*synuclein*and *parkin*maintain their ommatidial arrays and morphology (Figure [2E,2F](#F2){ref-type="fig"}). This observation demonstrates that directed expression of *parkin*suppresses α-*synuclein*-dependent degeneration of the ommatidial array.

Retinal damage can be observed by examining an optical effect termed the pseudopupil, which is lost in aged flies that express α-*synuclein*\[[@B32]\]. We examined flies that co-express α-*synuclein*and *parkin*, and there appeared to be some retention of this optical effect compared with flies that express α-*synuclein*alone (data not shown). Scanning electron microscopy of eyes revealed no obvious deterioration of the surface in flies that express α-*synuclein*(Figure [3A](#F3){ref-type="fig"} and [3D](#F3){ref-type="fig"}) or flies that co-express α-*synuclein*and *parkin*(Figure [3B,3C,3E](#F3){ref-type="fig"} and [3F](#F3){ref-type="fig"}). Although α-*synuclein*causes degeneration of the ommatidial array, the external structure of the eye is unaffected.

Directed-expression of *parkin*to dopaminergic neurons does not affect climbing ability
---------------------------------------------------------------------------------------

Young wild-type adult *Drosophila*exhibit a strong negative geotaxis, which is increased by mechanical stimulation \[[@B48],[@B49]\]. In order to measure climbing ability, flies are placed in a vial, gently tapped to the bottom and allowed to climb up the sides \[[@B32]\]. When *parkin*is expressed in the dopaminergic neurons, these flies do not show any change in their climbing ability over their life span when compared with controls (Figure [4A](#F4){ref-type="fig"}). In addition, expression of *parkin*in dopaminergic neurons does not alter life span (Figure [4B](#F4){ref-type="fig"}). These results demonstrate that *parkin*expression in the dopaminergic neurons has little effect upon climbing ability or life span.

Parkin suppresses α-*synuclein*induced loss of climbing ability
---------------------------------------------------------------

Flies that express α-*synuclein*, specifically in their dopaminergic neurons through the activity of the *Ddc-Gal4*transgene, were assayed for their climbing ability over their life span, and were found to prematurely lose their climbing ability (Figure [5A](#F5){ref-type="fig"}). Co-expression of *parkin*with α-*synuclein*suppresses this premature loss of climbing ability (Figure [5A](#F5){ref-type="fig"}). This suggests that *parkin*can act to prevent the deleterious effects of α-*synuclein*expression.

Aging assays were carried out in tandem with the climbing assays described above in order to account for changes in climbing ability as a result of premature senescence. Median survival age for flies that express α-*synuclein*is similar to flies that co-express α-*synuclein*with *parkin*(Figure [5B](#F5){ref-type="fig"}). This indicates that differences in climbing ability were not due to differences in life span.

Discussion
==========

*Drosophila parkin*has a high degree of similarity to the mammalian and *A. gambiae*homologues. The five characteristic domains of the parkin protein, the [Ub]{.ul}iquitin- [l]{.ul}ike Domain (UBL), [U]{.ul}nique [P]{.ul}arkin [D]{.ul}omain (UPD), [R]{.ul}eally [I]{.ul}nteresting [N]{.ul}ew [G]{.ul}ene finger 1 (RING1) domain, [I]{.ul}n- [B]{.ul}etween [R]{.ul}ing (IBR) domain and RING2 all show a high degree of similarity. In addition, the two dipterans, *D. melanogaster*and *A. gambiae*, have a highly conserved extra segment of 15 amino acids at the amino-terminal of the protein. The regions between the three carboxy-terminus domains are also highly conserved, which may indicate conservation of function. Patients with ARJP caused by mutations in the UBL domain exhibit signs of lost substrate binding \[[@B23]\]. The UBL domain also appears to be involved in binding the Rpn10 subunit of the 26S proteasome as the R42P amino acid substitution in this domain was identified in ARJP patients and results in impaired proteasome binding of parkin (Figure [6](#F6){ref-type="fig"}) \[[@B50]\]. Alterations of the RING1, RING2 and IBR domains of parkin result in an almost complete loss of ubiquitin conjugating enzyme H7 (UbcH7)-binding activity, which indicates that all three domains are functionally important in recruiting specific E2 ubiquitin conjugating enzymes \[[@B51]\]. The RING1 and RING2 domains are thought to collaborate to trap UbcH7 (Figure [6](#F6){ref-type="fig"}) \[[@B51]\]. Amino acid substitutions in the RING1 domain change the subcellular localization of parkin and enhance cytoplasmic and nuclear inclusions \[[@B52]\]. In addition, the amino acid substitutions C289G and C418R, which replace conserved cysteine residues in the RING domains, significantly decrease the solubility of parkin in cells \[[@B53]\]. Ubiquitination generally occurs near the amino-terminus of proteins and ubiquitin monomers are attached to lysine residues \[[@B25]\]. Several lysine residues are absolutely conserved, including one in the UBL and two in the UPD, and these may be targets for ubiquitination. The existence of orthologues of mammalian *parkin*in invertebrates but not plants nor fungi \[[@B54]\] suggest an animal specific function for *parkin*activity. The highly conserved protein domains and sub-domains suggest the probable conservation of each domain\'s function, and given the high degree of similarity we suggest that the function of the *Drosophila*parkin protein is similar to that of the human parkin protein.

We demonstrate that the directed expression of *parkin*in the dopaminergic neurons and developing eyes leads to no obvious adverse effects. The unaltered phenotype observed when *parkin*is expressed in dopaminergic neurons is likely due to substrate specificity and to the ability of the parkin protein to target itself for degradation \[[@B28]\]. Under conditions of over-expression, parkin does not seem to target and tag essential proteins for degradation promiscuously. This may represent an excellent fail-safe mechanism the cell has developed to balance the levels of both parkin and its substrates.

The *Drosophila*model of ADPD has been used to examine the effect of various pharmacological agents \[[@B34],[@B36]\] and other genetic aspects of the disease \[[@B35],[@B37]\]. We expressed *parkin*along with α-*synuclein*and found the suppression of α-*synuclein*-induced retinal degeneration and premature loss of climbing. These results indicate that parkin may target α-synuclein for degradation *in vivo*(Figure [6](#F6){ref-type="fig"}). Although coimmuno-precipitation studies have shown that parkin does not interact with or ubiquitinate non-modified α-synuclein \[[@B29]\], parkin will ubiquitinate O-glycosylated α-synuclein \[[@B26]\]. Since we show suppression of the α-*synuclein*-induced phenotype, we believe that ectopically expressed α-*synuclein*is modified in *Drosophila*, enabling its ubiquitination by parkin. The modification of α-synuclein and subsequent ubiquitination by parkin is presented in Figure [6](#F6){ref-type="fig"}.

In order to select rational potential therapeutic agents, the molecular mechanisms behind disease progression must be characterized. Gene function studies with homologues of disease-causing genes in model organisms have been made practical through the advent of genome projects. Over-expression of *parkin*has no apparent adverse consequences and it suppresses the α-*synuclein*-induced PD symptoms in *Drosophila*. If this relationship is conserved in humans, we suggest that up-regulation of *parkin*should be a viable treatment for PD, and the selection of therapeutic strategies should be directed towards this end.

Conclusions
===========

Our experiments demonstrate that the directed expression of the *parkin*gene counteracts the PD-like symptoms in the α-*synuclein*-induced *Drosophila*model of PD. Manipulation of the ubiquitin/proteasome degradation pathway in such a specific manner apparently remedies the toxic accumulation of α-synuclein. This study demonstrates the success of selective targeting of toxic proteins for degradation as an approach to address neurodegenerative conditions such as Parkinson\'s disease. The development of therapies that regulate *parkin*expression or parkin protein activity may be crucial in the treatment of PD.

Methods
=======

Bioinformatic and sequence analysis
-----------------------------------

The *Drosophila melanogaster*homologue of *parkin*was identified through a search of the Berkeley Drosophila Genome Project \[[@B55]\] queried with the human parkin amino acid sequence, AB009973.1. A clone of the *Drosophila parkin*cDNA (SD01679) was obtained from Research Genetics \[[@B56]\], sub-cloned and sequenced (Cortec DNA Service Laboratories Inc., Kingston, ON, Canada). The intron/exon map was constructed by comparison of the cDNA to the corresponding genomic region. Other homologues of *parkin*were identified with the tblastn algorithm \[[@B57]\] of the National Center for Biotechnology Information (NCBI) using the theoretical translation of SD01679 cDNA. The blast2 sequence comparison program (NCBI) was used to compare the *R. norvegicus*(NM_020093.1), *M. musculus*(AB019558.1) and *A. gambiae*(XM316606.1) sequences individually with the *D. melanogaster*parkin protein sequence \[[@B57]\]. The multi-alignment of the five parkin homologues from *D. melanogaster*, *A. gambiae*, *R. norvegicus*, *M. musculus*and *H. sapiens*was constructed by editing the results from the multialign ClustalW program from the Pôle Bio-Informatique Lyonnaise \[[@B58],[@B59]\].

Fly stocks and culture
----------------------

Dr. M. Feany (Harvard Medical School) and Dr. J. Hirsh (University of Virginia) generously provided *UAS-α-synuclein*\[[@B32]\] and *Ddc-Gal4*^4.36^flies \[[@B60]\] respectively. The *GMR-Gal4*flies \[[@B61]\] were obtained from the Bloomington Drosophila Stock Center at Indiana University. A *Bgl*II/*Xho*I fragment containing the *parkin*cDNA (SD01679) was subcloned into the *pUAST*vector to generate the *UAS-parkin*transgene. Two independent transgenic lines were generated using heat shock π as a source of transposase and standard injection techniques into *w*^1118^embryos. Double transgenic lines with *UAS-α-synuclein*;*UAS-parkin*^1.1^and *UAS-α-synuclein*;*UAS-parkin*^2.1^were generated using standard techniques. To drive expression of the transgenes, *Ddc-Gal4*(for expression in the dopaminergic neurons) or *GMR-Gal4*(for expression in the eye) homozygous females were crossed to *w*^1118^males (control) or *UAS-α-synuclein*with or without *UAS-parkin*^1.1^or *UAS-parkin*^2.1^. All flies were cultured on standard cornmeal/yeast/molasses/agar media at 25°C.

*In situ*hybridization analysis
-------------------------------

Third instar larvae were dissected in PBS, fixed in 4% formaldehyde and dehydrated in methanol and ethanol. The carcases were probed with a DIG labelled anti-sense *parkin*RNA probe generated from a linear cut plasmid containing the entire *parkin*cDNA using the Roche Applied Science DIG Northern starter kit and reduced in size with carbonate buffer treatment. To visualize *parkin*RNA alkaline phosphatase labelled anti-DIG anti-bodies were incubated with the carcases and subjected to alkaline phosphate treatment as per the Roche Applied Science DIG application manual. The eye discs were dissected out completely and examined under light microscopy. The genotypes of the larvae examined were 1) *w*^1118^; 2) *w*^1118^; *GMR-Gal4/+; UAS-parkin*^1.1^/+; and 3) *w*^1118^; *GMR-Gal4/+*; *UAS-parkin*^2.1^/+ and at least ten of each genotype were examined.

Aging analysis
--------------

Adult males were collected under gaseous carbon dioxide anaesthetic and aged in small groups (\~10 or less per vial) upon standard cornmeal/yeast/molasses/agar media at 25°C in upright standard plastic shell vials. The flies were scored for viability every two to three days and transferred to fresh media without anaesthesia \[[@B62]\]. The numbers of individuals aged are as follows: *UAS*-α-*synuclein*/+; *Ddc-Gal4*/+ = 191; *UAS*-α-*synuclein*/+; *UAS-parkin*^2.1^/*Ddc-Gal4*= 292; *UAS*-α-*synuclein*/+; *UAS-parkin*^1.1^/*Ddc-Gal4*= 204; *w*^1118^; *Ddc-Gal4/+*= 173; *UAS-parkin*^1.1^/*Ddc-Gal4*= 262; and *UAS-parkin*^2.1^/*Ddc-Gal4*= 227.

Locomotion assay
----------------

Flies were assayed for their ability to climb as described by Feany and Bender \[[@B32]\]. Every five days, forty male flies from a cohort of flies were assayed for their ability to climb six centimetres in eighteen seconds in a sterile plastic vial. Twenty trials were carried out for each time point. Data shown represent the results from flies tested over ninety days.

Scanning electron microscopy of the *Drosophila*eye
---------------------------------------------------

Flies were of each genotype \[1) *w*^1118^; *UAS*-α-*synuclein/GMR-Gal4*; 2) *w*^1118^; *UAS*-α-*synuclein/GMR-Gal4*; *UAS-parkin*^1.1^/+; and 3) *w*^1118^; *UAS*-α-*synuclein/GMR-Gal4*; *UAS-parkin*^2.1^/+\] aged and frozen in a -70°C ethanol bath. Whole flies were mounted, desiccated overnight and coated in gold before photography at 150 times magnification with a Hitachi S-570 SEM as per standard methods. For each condition at least six flies were analysed.

Histological examination of *Drosophila*adult retinas
-----------------------------------------------------

Adult flies \[1) *w*^1118^; *UAS*-α-*synuclein/GMR-Gal4*; 2) *w*^1118^; *UAS*-α-*synuclein/GMR-Gal4*; *UAS-parkin*^1.1^/+; and 3) *w*^1118^; *UAS*-α-*synuclein/GMR-Gal4*; *UAS-parkin*^2.1^/+\] were aged (one or thirty days after eclosion), fixed in Karnovsky\'s fixative and embedded in epon. Tangential retinal sections were prepared at a thickness of 0.5 μm and stained with toluidine blue, examined by light microscopy and photographed at magnification of 800 times.
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Figures and Tables
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![**Dipteran and mammalian parkin proteins are well conserved**. (A) Schematic representation of the *Drosophila melanogaster*parkin transcription unit and its location in the genomic scaffolding region AE003593. (B) ClustalW alignment of the *Drosophila melanogaster*parkin with homologues from *Anopheles gambiae*, *Rattus norvegicus*, *Mus musculus*and *Homo sapiens*. Highlighted are the Ubiquitin-like Domain (UBL) (green box); the Unique Parkin Domain (UPD) (red box); RING1 and RING2 (blue boxes); In-Between Ring Domain (IRB) (black box). \"\*\" and red lettering indicates amino acids that are identical in all sequences in the alignment. \":\" and green lettering indicates conserved substitutions. \".\" and blue lettering indicates semi-conserved substitutions.](1471-2202-5-14-1){#F1}

![**Expression of *parkin*suppresses α-*synuclein*-induced retinal degeneration**. Flies that express α-*synuclein*with and without *parkin*were aged to 1 or 30 days old. They were fixed and embedded in epon. Tangential sections (0.5 μm thick) of the retina were cut, stained with toludine blue and examined by light microscopy. Panels A-C represent one-day-old flies and panels D-F represent thirty-day-old flies. Black arrows indicate degeneration of the ommatidial architecture. The genotypes are (A,D) *w*^1118^; *UAS*-α-*synuclein/GMR-Gal4*, (B,E) *w*^1118^; *UAS*-α*-synuclein/GMR-Gal4*; *UAS-parkin*^1.1^/+, and (C,F) *w*^1118^; *UAS*-α-*synuclein/GMR-Gal4*; *UAS-parkin*^2.1^/+. Scale bar is 15 μm.](1471-2202-5-14-2){#F2}

![**Expression of α-*synuclein*with and without *parkin*does not affect the external morphology of the eye**. Scanning electron microscopy of flies that express α-*synuclein*with and without *parkin*shows no change in their external morphology over thirty days. Panels A-C represent one-day-old flies and panels D-F represent thirty-day-old flies. The genotypes are (A,D) *w*^1118^; *UAS*-α-*synuclein/GMR-Gal4*, (B,E) *w*^1118^; *UAS*-α-*synuclein/GMR-Gal4*; *UAS-parkin*^1.1^/+, and (C,F) *w*^1118^; *UAS*-α-*synuclein/GMR-Gal4*; *UAS-parkin*^2.1^/+. Scale bar indicates 200 μm.](1471-2202-5-14-3){#F3}

![**Expression of *parkin*does not affect climbing ability or life span**. Panel A -- Climbing ability of flies that express *parkin*does not differ from control flies. Genotypes are *w*^1118^; *UAS-parkin*^1.1^/*Ddc-Gal4*(green open triangle), *w*^1118^; *UAS-parkin*^2.1^/*Ddc-Gal4*(orange open square) and *w*^1118^; *Ddc-Gal4/+*(black open circles). The error bars show the standard error of the mean of twenty trials at each point. Please note that the error bars are mostly within the symbols. B -- The life span of flies that express *parkin*does not differ from the control. The genotypes are marked the same as in panel A. The mortality of flies was examined every two days.](1471-2202-5-14-4){#F4}

![**Expression of *parkin*suppresses α-*synuclein*-induced loss of climbing ability**. Panel A -- Aged flies that express *parkin*and α-*synuclein*climb significantly better than flies that express α-*synuclein*(P \< 0.001, one-way analysis of variance with supplementary Newman-Keuls test). Genotypes are *w*^1118^; *UAS*-α-*synuclein/+*; *Ddc-Gal4/+*(green open square), *w*^1118^; *UAS*-α-*synuclein/+*; *UAS-parkin*^1.1^/*Ddc-Gal4*(red open triangle), *w*^1118^; *UAS*-α-*synuclein/+*; *UAS-parkin*^2.1^/*Ddc-Gal4*(blue upside down open triangle). The error bars show the standard error of the mean of twenty trials at each point. Please note that the error bars are mostly within the symbols. B -- The life span of flies that express α-*synuclein*with and without *parkin*does not differ. The genotypes are marked the same as in panel A.](1471-2202-5-14-5){#F5}

![**Model of parkin directed ubiquitination of α-synuclein**. The parkin protein consists of two functionally distinct regions. The UBL/UPD region binds target proteins such as glycosylated α-synuclein. The RING-box (RING1-IBR-RING2) region recruits specific E2 ubiquitin conjugating enzymes, which add ubiquitin monomers to the target protein. In addition to substrate binding the UBL domain interacts with the proteasome. Ubiquitin tagged α-synuclein is directed to the proteasome and degraded into polypeptides and ubiquitin monomers. UBL -- [Ub]{.ul}iquitin-[l]{.ul}ike Domain, UPD -- [U]{.ul}nique [P]{.ul}arkin [D]{.ul}omain, RING1 or 2 -- [R]{.ul}eally [I]{.ul}nteresting [N]{.ul}ew [G]{.ul}ene finger 1 or 2 domain, IBR -- [I]{.ul}n-[B]{.ul}etween [R]{.ul}ing domain.](1471-2202-5-14-6){#F6}
